Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.81 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 05, 2022

Via Benzinga

$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying ↗

December 05, 2022

Although US stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Iovance Biotherapeutics to Present at Upcoming Conferences

November 30, 2022

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock ↗

November 21, 2022

Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on...

Via Benzinga

What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics ↗

November 21, 2022

Via Benzinga

Recap: Iovance Biotherapeutics Q3 Earnings ↗

November 03, 2022

Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Expert Ratings for Iovance Biotherapeutics ↗

August 05, 2022

Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings:

Via Benzinga

7 Analysts Have This to Say About Iovance Biotherapeutics ↗

July 01, 2022

Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Iovance Biotherapeutics Is Crashing Today ↗

November 18, 2022

The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.

Via The Motley Fool

Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate ↗

November 18, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 18, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

November 18, 2022

It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

November 18, 2022

BLA Submission Ongoing with U.S. Food and Drug Administration

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 10, 2022

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 07, 2022

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates

November 03, 2022

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Preview: Iovance Biotherapeutics's Earnings ↗

November 02, 2022

Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022

October 24, 2022

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

October 10, 2022

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

October 05, 2022

Oral Presentation of C-144-01 Trial Cohorts 2 and 4

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

5 Top Stocks Cathie Wood Is Selling This Week ↗

August 26, 2022

Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling.

Via InvestorPlace

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 25, 2022

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Iovance Biotherapeutics: Q2 Earnings Insights ↗

August 04, 2022

Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022

July 27, 2022

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

69 Biggest Movers From Friday ↗

June 06, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...

Via Benzinga

40 Stocks Moving In Friday's Mid-Day Session ↗

June 03, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Via Benzinga

Insiders Buy Around $10M Of 3 Stocks ↗

June 03, 2022

Although the Dow Jones jumped more than 400 points on Thursday, there were a few notable insider trades.

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.